EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination

Henrik E Mei iD, Axel Ronald Schulz, Heike Hirseland, Lisa-Marie Diekmann, Elisa Habermann, Alexander Ten Hagen, Fredrik Albach iD, Gerd-Rüdiger Burmester, Andreas Grützkau, Robert Biesen

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Henrik E Mei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), a Leibniz Institute, Berlin, Germany. Hauptthemen laut MEDLINE: COVID-19, B-Lymphocytes, Spike Glycoprotein, Coronavirus, Antibodies, Viral. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Innovative Medicines Initiative, Senatsverwaltung für Bildung, Jugend und Wissenschaft, Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Active and passive immunization is used in high‐risk patients to prevent severe courses of COVID‐19, but the impact of prophylactic neutralizing antibodies on the immune reaction to the mRNA vaccines has remained enigmatic. Here we show that CD4 T and B cell responses to Spikevax booster immunization are suppressed by the therapeutic antibodies Casirivimab and Imdevimab. B cell and T cell responses were significantly induced in controls but not in antibody‐treated patients. The data indicates that humoral immunity, i. e. high levels of antibodies, negatively impacts reactive immunity, resulting in blunted cellular responses upon boosting. This argues for temporal separation of vaccination efforts; with active vaccination preferably applied before prophylactic therapeutic antibody treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19B-LymphocytesSpike Glycoprotein, CoronavirusAntibodies, ViralAntibodies, NeutralizingCOVID-19 VaccinesSARS-CoV-2HumansMiddle AgedMaleFemaleVaccinationAdultAgedCD4-Positive T-LymphocytesT-LymphocytesImmunization, SecondaryImmunity, HumoralAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

COVID‐19CasirivimabImdevimabRonapreveSARS‐CoV‐2active vaccinationantibody feedbackimmunocompromised patientsmRNA vaccinationneutralizationnonresponderspassive immunizationrituximab

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, ViralAntibodies, NeutralizingCOVID-19 Vaccinesspike protein, SARS-CoV-2Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), a Leibniz Institute, Berlin, Germany.
  • Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

ORCID-Profile: Henrik E Mei, Fredrik Albach

Förderung

  • Deutsche Forschungsgemeinschaft
  • Innovative Medicines Initiative
  • Senatsverwaltung für Bildung, Jugend und Wissenschaft, Berlin

Zitieren

APA

Mei, H. E., Schulz, A. R., Hirseland, H., Diekmann, L. M., Habermann, E., Ten Hagen, A., Albach, F., Burmester, G. R., Grützkau, A., & Biesen, R. (2024). Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination. Journal of Medical Virology. https://doi.org/10.1002/jmv.29778

Vancouver

Mei HE, Schulz AR, Hirseland H, Diekmann LM, Habermann E, Ten Hagen A, et al. Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination. Journal of Medical Virology. 2024. doi:10.1002/jmv.29778

BibTeX
@article{Mei2024,
  author = {Mei, Henrik E and Schulz, Axel Ronald and Hirseland, Heike and Diekmann, Lisa-Marie and Habermann, Elisa and Ten Hagen, Alexander and Albach, Fredrik and Burmester, Gerd-Rüdiger and Grützkau, Andreas and Biesen, Robert},
  title = {Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29778}
}
Kostenlos starten →